Get the Stockscreener App
8.03
2.91%
0.12
Immunome Inc stock is traded at $8.03, with a volume of 556.63K.
It is up +2.91% in the last 24 hours and down -0.49% over the past month.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
See More
Previous Close:
$7.91
Open:
$7.8
24h Volume:
556.63K
Relative Volume:
0.50
Market Cap:
$639.09M
Revenue:
-
Net Income/Loss:
$-106.81M
P/E Ratio:
-2.4247
EPS:
-3.3117
Net Cash Flow:
$-8.40M
1W Performance:
+10.75%
1M Performance:
-0.49%
6M Performance:
-31.65%
1Y Performance:
-47.42%
1-Day Range:
$7.7557
$8.40
1-Week Range:
$6.96
$8.40
52-Week Range:
$5.1501
$16.81
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
8.03 | 639.09M | 0 | -106.81M | -8.40M | -3.3117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.65 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.24 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.39 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
229.65 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
228.36 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | Lake Street | Buy |
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
Immunome: Transformed Pipeline Offers Multiple Catalysts (NASDAQ:IMNM) - Seeking Alpha
JPMorgan Chase & Co. Acquires 624,045 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
How To Trade (IMNM) - news.stocktradersdaily.com
Wellington Management Group LLP Raises Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Vanguard Group Inc. Sells 128,130 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
Immunome Announces Management Changes - marketscreener.com
KLP Kapitalforvaltning AS Invests $75,000 in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Corebridge Financial Inc. Sells 1,929 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
Commonwealth Equity Services LLC Buys Shares of 19,017 Immunome, Inc. (NASDAQ:IMNM) - Defense World
Raymond James Financial Inc. Acquires Shares of 25,817 Immunome, Inc. (NASDAQ:IMNM) - Defense World
Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last? - Yahoo Finance
Brokerages Set Immunome, Inc. (NASDAQ:IMNM) PT at $25.14 - Defense World
Immunome stock hits 52-week low at $5.5 amid market challenges - Investing.com
Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference - BioSpace
Immunome's Latest Cancer Therapy Progress: Key Investor Presentation Coming to Needham Conference - Stock Titan
Lake Street Capital Begins Coverage on Immunome (NASDAQ:IMNM) - Defense World
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Joplin Globe
Teacher Retirement System of Texas Purchases New Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Clay Siegall Bought 20% More Shares In Immunome - simplywall.st
Corient Private Wealth LLC Sells 12,149 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
Immunome stock hits 52-week low at $6.94 amid market challenges - Investing.com Australia
Immunome stock hits 52-week low at $6.94 amid market challenges By Investing.com - Investing.com South Africa
Immunome (NASDAQ:IMNM) Stock Price Up 4.4% After Insider Buying Activity - Defense World
Immunome (IMNM) Stock Climbs as Executives Increase Holdings - GuruFocus
Immunome director Jean Jacques Bienaime acquires $60,684 in stock - Investing.com
Immunome director Jean Jacques Bienaime acquires $60,684 in stock By Investing.com - Investing.com South Africa
Immunome CEO Clay Siegall buys $999k in stock By Investing.com - Investing.com Canada
Immunome CEO Clay Siegall buys $999k in stock - Investing.com India
Immunome stock rises after insider purchase (IMNM:NASDAQ) - Seeking Alpha
Immunome stock rises after insider purchase - MSN
Immunome director Jean Jacques Bienaime purchases $57,470 in stock By Investing.com - Investing.com Canada
Charles Schwab Investment Management Inc. Increases Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Immunome CTO Philip Tsai purchases $103,566 in stock By Investing.com - Investing.com Canada
Immunome director Jean Jacques Bienaime purchases $57,470 in stock - Investing.com
Immunome CTO Philip Tsai purchases $103,566 in stock - Investing.com
Bank of New York Mellon Corp Has $1.31 Million Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Wedbush Has Positive Estimate for Immunome Q1 Earnings - Defense World
Immunome (NASDAQ:IMNM) Receives Outperform Rating from Wedbush - MarketBeat
Immunome’s (IMNM) “Outperform” Rating Reiterated at Wedbush - Defense World
Guggenheim Has Lowered Expectations for Immunome (NASDAQ:IMNM) Stock Price - Defense World
Stephens Reiterates Overweight Rating for Immunome (NASDAQ:IMNM) - Defense World
Trading (IMNM) With Integrated Risk Controls - news.stocktradersdaily.com
Immunome Full Year 2024 Earnings: Misses Expectations - Yahoo
Immunome’s 2024 Financial Results and Pipeline Progress - TipRanks
Immunome stock target cut to $25 by Guggenheim - Investing.com Australia
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunome Inc Stock (IMNM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | Director |
Mar 25 '25 |
Buy |
7.78 |
7,800 |
60,684 |
31,415 |
| SIEGALL CLAY B | President and CEO |
Mar 26 '25 |
Buy |
7.29 |
137,100 |
999,459 |
806,736 |
| BIENAIME JEAN JACQUES | Director |
Mar 24 '25 |
Buy |
8.21 |
7,000 |
57,470 |
23,615 |
| Tsai Philip | Chief Technology Officer |
Mar 24 '25 |
Buy |
8.42 |
12,300 |
103,566 |
33,300 |
| SIEGALL CLAY B | President and CEO |
Jan 31 '25 |
Buy |
7.75 |
150,000 |
1,162,500 |
669,636 |
| SIEGALL CLAY B | President and CEO |
Nov 21 '24 |
Buy |
9.54 |
66,057 |
630,263 |
485,693 |
| SIEGALL CLAY B | President and CEO |
Nov 22 '24 |
Buy |
9.78 |
33,943 |
331,918 |
519,636 |
| Lechleider Robert | Chief Medical Officer |
Nov 21 '24 |
Buy |
9.48 |
15,805 |
149,800 |
15,805 |
| Tsai Philip | Chief Technology Officer |
Nov 21 '24 |
Buy |
9.43 |
21,000 |
198,030 |
21,000 |
| Rosett Max | Chief Financial Officer |
Sep 19 '24 |
Option Exercise |
1.05 |
42,000 |
44,100 |
61,856 |
0.77%
0.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):